Table 2.
Phenotyping analysis of CD45 positive cells from peripheral blood and malignant ascites from 53 patients with ovarian cancer
| Cell population | Peripheral blood (%) | Ascites (%) | p |
|---|---|---|---|
| CD3+ | 70.9 (61.8–75.1) | 75.0 (71.1–82.4) | 0.097 |
| CD3+/CD69+ | 0.8 (0.2–2.1) | 6.7 (4.5–15.2) | < 0.001 |
| CD3+/CD25+ | 4.9 (3.6–5.8) | 3.7 (2.4–5.3) | 0.381 |
| CD3+/DR+ | 1.4 (0.7–2.8) | 4.0 (1.1–7.0) | 0.068 |
| CD3+/CD4+ | 48.7 (39.1–57.1) | 49.1 (34.1–52.0) | 0.446 |
| CD4+/45RA+ | 8.5 (2.7–11.0) | 2.6 (1.3–5.7) | 0.007 |
| CD4+/45RO+ | 30.6 (19.2–34.2) | 37.7 (25.3–45.1) | 0.013 |
| CD8+ | 21.1 (15.7–24.8) | 30.0 (20.3–36.6) | 0.033 |
| CD3+/CD8+ | 19.1(17.1–20.8) | 28.7 (16.8–33.2) | 0.012 |
| CD3–/8+ | 2.9 (1.2–6.5) | 3.9 (3.0–4.9) | 0.205 |
| CD8+/DR+ | 0.6 (0.3–1.4) | 2.3 (0.7–5.3) | <0.001 |
| CD+/CDaβ+ | 25.6 (8.8 | 37.4 (19.9–52.6) | 0.065 |
| CD8+/CDγδ+ | 0.5 (0.2–2.5) | 0.4 (02–0.8) | 0.698 |
| CD8+/CD57+ | 3.8 (2.7–6.9) | 1.3 (0.5–8.1) | 0.235 |
| CD19+ | 10.6 (7.8–16.7) | 6.8 (4.1–8.6) | 0.009 |